Biohaven Ltd.

Biohaven Ltd.

BHVN·NYSE

$10.81

+6.7%
HealthcareBiotechnology

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

At a Glance

Live Snapshot
Market Cap$1.14B
EPS-6.8600
P/E Ratio-1.58
Earnings Date08/10/2026

bhvn

Change in Working Capital

Last Annual Value

1.36M

3-Year CAGR

27%

5-Year CAGR

-31%

10-Year CAGR

-10%

Biohaven Ltd.

Biohaven Ltd. Competitors Analysis of Change in Working Capital

BHVN · NYSE
CompanyChange in Working Capital
CAGR 3Y
CAGR 5Y
CAGR 10Y
BHVN logo
Biohaven Ltd.
NYSE:BHVN
1.36M
-61.9%-4.0%N/A 
-73.75M
N/AN/AN/A
IMNM logo
Immunome, Inc.
NASDAQ:IMNM
-15.23M
N/AN/AN/A
22.99M
N/A45.6%N/A
-2.65M
N/AN/AN/A
951.00K
N/AN/AN/A
-10.36M
N/AN/AN/A
14.06M
1.5%N/AN/A
Biohaven Ltd.

Biohaven Ltd. Fair Value Envelope

BHVN · NYSE

Our analysis suggests that BHVN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $10.81, this represents a potential HIDDEN relative to our calculated worth for Biohaven Ltd..

Intrinsic Value
Current Price: $10.81